Literature DB >> 31478058

[Influenza].

C Malainou1, S Herold2.   

Abstract

BACKGROUND: The influenza virus (IV)-associated mortality and morbidity remains high in Europe.
OBJECTIVE: This article gives an overview of the pathogenesis, diagnostics and treatment optimization strategies according to the currently existing guidelines and clinical trials.
MATERIAL AND METHODS: Literature search and analysis of national and international guidelines for the epidemiology, diagnostics, treatment and prevention of IV infections. RESULTS AND
CONCLUSION: Although the incidence of IV infections remains underrecognized, it is the leading infectious disease-associated cause of mortality and morbidity in Europe. Viruses are mainly transmitted by aerosol inhalation and can cause a wide spectrum of symptoms, ranging from mild signs of a cold to severe respiratory failure requiring mechanical ventilation. The clinical diagnosis should be verified through a PCR-based test in patients with indications for treatment. Neuraminidase inhibitors are currently the treatment of choice for IV infections. Seasonal influenza vaccination is an efficient preventive method. It is therefore imperative to improve vaccination rates in Germany, which have been continuously declining since the pandemic of 2009/2010.

Entities:  

Keywords:  Acute respiratory distress syndrome; Influenza vaccines, seasonal; Neuraminidase inhibitors; Pneumonia, viral, influenza; Polymerase chain reaction

Mesh:

Substances:

Year:  2019        PMID: 31478058     DOI: 10.1007/s00108-019-00670-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  40 in total

1.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

2.  Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.

Authors:  Jeffrey C Kwong; Kevin L Schwartz; Michael A Campitelli; Hannah Chung; Natasha S Crowcroft; Timothy Karnauchow; Kevin Katz; Dennis T Ko; Allison J McGeer; Dayre McNally; David C Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; George Zahariadis; Jonathan B Gubbay
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

3.  Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study.

Authors:  Itziar Casado; Ángela Domínguez; Diana Toledo; Judith Chamorro; Jenaro Astray; Mikel Egurrola; María Amelia Fernández-Sierra; Vicente Martín; María Morales-Suárez-Varela; Pere Godoy; Jesús Castilla
Journal:  CMAJ       Date:  2018-01-08       Impact factor: 8.262

Review 4.  Current and future influenza vaccines.

Authors:  Seiya Yamayoshi; Yoshihiro Kawaoka
Journal:  Nat Med       Date:  2019-01-28       Impact factor: 53.440

Review 5.  Emergence and pandemic potential of swine-origin H1N1 influenza virus.

Authors:  Gabriele Neumann; Takeshi Noda; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

Review 6.  The rationale for quadrivalent influenza vaccines.

Authors:  Christopher S Ambrose; Myron J Levin
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

Review 7.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

Review 8.  Human Influenza Virus Infections.

Authors:  Christin Peteranderl; Susanne Herold; Carole Schmoldt
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

Review 9.  Review of aerosol transmission of influenza A virus.

Authors:  Raymond Tellier
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

10.  The burden of seasonal and pandemic influenza in infants and children.

Authors:  Bernhard R Ruf; Markus Knuf
Journal:  Eur J Pediatr       Date:  2013-05-10       Impact factor: 3.183

View more
  5 in total

1.  Chest multidetector computed tomography imaging of COVID-19 pneumonia patients with hematologic malignancies.

Authors:  Adel El-Badrawy; Nada Elbadrawy
Journal:  Blood Res       Date:  2022-08-03

Review 2.  Coronavirus Disease 2019 (COVID-19): A Perspective from China.

Authors:  Zi Yue Zu; Meng Di Jiang; Peng Peng Xu; Wen Chen; Qian Qian Ni; Guang Ming Lu; Long Jiang Zhang
Journal:  Radiology       Date:  2020-02-21       Impact factor: 11.105

Review 3.  A Review of SARS-CoV-2 and the Ongoing Clinical Trials.

Authors:  Yung-Fang Tu; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Yi-Ying Lin; Yung-Hung Luo; Yi-Tsung Lin; Wei-Yi Lai; De-Ming Yang; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

4.  Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis.

Authors:  Cuiping Bao; Xuehuan Liu; Han Zhang; Yiming Li; Jun Liu
Journal:  J Am Coll Radiol       Date:  2020-03-25       Impact factor: 6.240

Review 5.  The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy.

Authors:  Ranjan K Mohapatra; Lucia Pintilie; Venkataramana Kandi; Ashish K Sarangi; Debadutta Das; Raghaba Sahu; Lina Perekhoda
Journal:  Chem Biol Drug Des       Date:  2020-07-26       Impact factor: 2.873

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.